Table 6.
Effect of Diabegon® on liver functions in MetS with Non-insulin dependent diabetes mellitus subjects of different age groups (N=58)
| (Group) | SGOT (IU/L) | SGPT (IU/L) | Total Bilirubin (mg/dl) | |||||||||
| Initial (a) |
6 month of therapy (b) |
12 month of therapy (c) |
18 month of therapy (d) |
Initial (a) | 6 month of of therapy (b) |
12 month of therapy (c) |
18 month of therapy (d) |
Initial (a) |
6 month of therapy (b) |
12 month of therapy(c) |
18 month of therapy (d) |
|
|
Group I (35–50) ,N=10 |
29.2±9.8 | 14.9±3.2 a** | 23.9±2 b** |
20.5±7 a*b* |
31.5±12.1 | 19.5±9.1 a* |
29.9±4 b* |
28.2±18 | 0.6±.05 | 0.7±.10 a* |
0.76±0.14 a* |
0.65±.05 a*c* |
|
Group II (51–65) ,N=34 |
24.6±2.3 | 30±8.7 a** |
32.3±3.1 a**b* |
26.4±10.2 b**c* |
29.4±1.9 | 30.1±7 | 32.8±20.8 b* |
16.3±3.2 a**b**c** |
0.81±.34 | 0.72±.19 | 0.94±.45 b* |
0.52±.26 a**b**c** |
|
Group III >65, N=14 |
24.9±3.8 | 32.2±5.2 a** | 30.9±2 a** |
21.7±3.7 a*b**c** |
29.9±5.7 | 32.9±2.3 | 30.7±6.3 | 20.8±8.5 a*b**c* |
0.74±.06 | 0.83±.12 a* |
0.9±.1 a** |
0.66±.15 b*c** |
|
CB-IV, N=43 FBS<145.9 |
29.2±7.8 | 18.1±3 a** |
30.2±3.7 | 24.5±6.3 a*b**c** |
33.9±9.8 | 16±4.4 a** |
27.3±3.07 a**b** |
17.6±3.3 a**b*c** |
0.84±.08 | 0.71±.18 a** |
0.91±.42 b* |
0.67±.22 a**c* |
|
CB-V, N=15 FBS>145.9 |
22.7±2.3 | 30.3±6 a** |
23.8±6.8 b* |
15.8±3.2 a**b**c** |
25.5±5.9 | 32.8±4.3 a** |
26.8±1.3 b** |
22.1±16 b* |
0.83±.03 | 0.54±.3 a* |
0.71±.03 a** |
0.85±.02 a*b*c** |
FBS, fasting blood sugar; CB, Combination, data were analyzed by ANOVA Bonferroni t-test. Levels of significance were represented in the form of bcdefghP<0.001(**),bcdefghP<0.05(*) when compared with initial (a) group.